CIDEB iRNA Compositions for NASH Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) and other chronic inflammatory diseases of the liver are inadequate, as they often rely on passive blockade of pro-inflammatory mediators, failing to address the self-perpetuating cycle of inflammation and tissue damage.
Innovation Solution
The use of iRNA compositions that target the CIDEB gene to inhibit its expression through RNA-induced silencing complex-mediated cleavage, providing a proactive approach to reduce liver inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If passive blockade of pro-inflammatory mediators is used to treat NASH, then inflammation is temporarily suppressed, but the self-perpetuating cycle of inflammation and tissue damage continues
Solution Approach 1:
The patent applies preliminary action by using iRNA compositions to silence CIDEB gene expression before it can drive the self-perpetuating cycle of inflammation. By targeting and reducing CIDEB levels upfront, the invention prevents the subsequent release of proinflammatory DAMPs and cytokines that would otherwise sustain chronic inflammation and tissue damage in NASH
Solution Approach 2:
The patent replaces the mechanical/passive blockade approach of traditional anti-inflammatory medications with a molecular biological mechanism. Instead of physically blocking inflammatory mediators, the invention uses RNA interference to specifically silence the CIDEB gene at the molecular level, thereby eliminating the source of proinflammatory signals that drive NASH progression
2Object-affected harmful factors
If CIDEB gene expression is inhibited using iRNA compositions, then liver inflammation is reduced, but selective and efficient inhibition of the target gene is required to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing iRNA compositions with highly specific nucleotide sequences that target only the CIDEB gene. The sense and antisense strands are engineered to match specific regions of the CIDEB mRNA, ensuring that the RNA-induced silencing complex selectively cleaves only the intended target transcript while leaving other genes unaffected, thus achieving localized and precise gene inhibition
Solution Approach 2:
The patent uses molecular recognition mechanisms where the iRNA compositions exploit base-pairing specificity to identify and bind to the CIDEB mRNA. This molecular-level targeting replaces non-specific anti-inflammatory mechanisms, allowing precise inhibition of the target gene through complementary sequence matching between the antisense strand and CIDEB transcript
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The iRNA compositions effectively inhibit CIDEB gene expression, disrupting the cycle of inflammation and tissue damage in liver diseases like NASH, promoting physiological pro-resolving mechanisms.
Implementation Method 1
iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a cell death-inducing DFFA-like effector b (CIDEB) gene
Data Source
AI summary
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CIDEB gene, as well as methods of inhibiting expression of CIDEB, and methods of treating subjects that would benefit from reduction in expression of CIDEB, such as subjects having a CIDEB-associated disease, disorder, or condition, using such dsRNA compositions.